Santosh 2006.
| Methods | 2 separate retrospective cohort studies (only study 2 is used here due to polypharmacy) | |
| Participants | Number of participants screened: not stated Number of participants included: 52 (ADHD: 25, ADHD + ASD: 27) Number of participants followed up: 52 Number of withdrawals: not stated Diagnosis of ADHD: DSM‐IV (subtype: not stated) Age: mean 11.08 years old IQ: mean 89.56 Sex: ADHD group 80% males, 20% females. ADHD + ASD group 88.89% males, 11.11% females Methylphenidate‐naïve: not stated Ethnicity: not stated Country: UK Comorbidity: not stated Comedication: not stated Sociodemographics: not stated Inclusion criteria
|
|
| Interventions | Methylphenidate type: not stated Methylphenidate dosage: not stated Administration schedule: not stated Duration of intervention: range of follow‐up was between 1 and 6 months, mean: 87 days Treatment compliance: not stated |
|
| Outcomes | Non‐serious adverse events Pre‐ and post‐treatment: routine ratings using the side effects module of the Treatment Outcome Rating Scale | |
| Notes | Sample calculation: no Ethics approval: not stated Funding/vested interests: both the pilot study and current development and deployment of the DENEM™ system have been supported by an award from Guys' and St Thomas' Charity Authors' affiliations: no affiliations to pharmaceutical companies stated Key conclusions of the study authors: both studies presented here support previous findings from smaller studies that show children with autism and ADHD can respond as well to stimulants as children with ADHD alone. Although randomised controlled trials remain the gold standard for efficacy studies, systems like this that allow clinicians to continue rigorous and consistent monitoring for many years have a valuable role to play. Furthermore, such monitoring systems which now exist electronically can easily accumulate large data sets and reveal details about long‐term effectiveness and long‐term side effects of medication that are unlikely to be discovered in short‐term trials Comments from the review authors: the article describes 2 studies. Some of the participants in the first study are not receiving MPH but dexamphetamine instead, and for this reason the first study is excluded from our review. The second described study is included Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: not stated Supplemental information and data have not been possible to retrieve through personal email correspondence with the authors in February‐June 2014 |
|